NFE2L2 and sarcopenia: Moreover, the activation of inflammatory pathways, including mammalian target of rapamycin (mTOR) and nuclear factor erythroid-related factor 2 (Nrf-2) signalling, appears to be involved in the pathophysiology of sarcopenia and frailty [2].